Waters' 240 P/E Is a Mirage: How the BD Deal Doubled the Business — and Priced In the Turnaround

A $40 billion life-science giant that just reported a $1.39-per-share loss for its latest quarter, yet trades near a 52-week high and has run up 36% in four months — that is the shape of Waters Corporation (NYSE: WAT) heading into its fireside chat at the J.P. Morgan All Stars Conference on September 23. The headline number is the trap. The story underneath is one giant, tax-savvy merger that wrecked the accounting but doubled the company.

Why the 240 P/E is a distraction

Any fundamentals pull on Waters today surfaces the same absurdity: trailing P/E around 240, return on equity under 2%, and a recent GAAP operating loss. Every one of those metrics is a victim of purchase accounting tied to one deal.

In February, Waters closed an ~$18.8 billion combination with Becton, Dickinson's Biosciences and Diagnostic Solutions business, structured as a Reverse Morris Trust that let BD spin the unit out and merge it into Waters on a tax-advantaged basis. BD shareholders received 39.2% of the combined company and $4 billion in cash; Waters, in effect, bought a roughly equal-size growth engine with stock and debt.

The accounting fog is the point. In the second quarter alone, closing the deal drove ~$155 million of inventory and fixed-asset step-ups through cost of revenue and ~$244 million of purchased-intangible amortization through operating expenses, and it roughly quintupled quarterly interest expense to $55 million. That stack of non-cash and financing charges flipped a profitable quarter into the $1.39 GAAP loss. When a reported income statement is this distorted, the trailing P/E, the ROE, and even the 47x trailing EV/EBITDA become noise rather than signal.

The cleaner scorecard

Ditch the GAAP column and the picture sharpens. EPS came in at $3.05, up 3% from a year ago, on total reported revenue of $1.645 billion. Roughly half of that revenue — $817 million — came from the acquired businesses, while the legacy analytical segment grew organically 7% as reported and 9% in constant currency. Management took the opportunity of a beat to raise every component of full-year guidance: ~$6.4–6.5 billion of total revenue, organic constant-currency growth of 7% to 9%, and adjusted EPS of $14.45–$14.65, or 10% to 12% growth.

That last figure gives the cleanest valuation read. At about $408 a share, Waters works out to roughly 28x forward adjusted earnings — no longer a 240x curiosity, but not a bargain either.

The premium versus its peers

Now the sector-relative question this framework actually exists to ask: relative to whom, and relative to what?

Put Waters next to the diversified life-science and diagnostics names it now competes with directly. Thermo Fisher trades around 24x EV/EBITDA, Danaher around 21x, Abbott around 19x — and all three carry meaningfully lower price-to-sales multiples than Waters' ~8.6x. On the adjusted earnings basis, Waters is the expensive one in the group.

The market is paying up for two things: faster growth, and option value on a turnaround. Organic growth of 9% plus a management team pushing the acquired units toward mid-single-digit acceleration under a 180-day revitalization plan is a genuinely improving report card — the kind of trajectory shift, with guidance raised across all lines, that justifies a higher multiple than a static, fully mature peer. Momentum confirms the timing read: price sits above its 50- and 200-day averages, RSI near 53, having retraced from a June high rather than collapsing.

What the fancy price actually buys — and what it owns

That premium is not free money, and naming the risks is exactly the discipline this calls for. The balance sheet that used to be a fortress now carries roughly $4.5 billion of net debt, and while the deal added real revenue, it also added about $9.4 billion of goodwill and $8.5 billion of intangibles against $24.7 billion of total assets. Something close to three-quarters of the balance sheet is now accounting that must be earned back through cash flow. Integration — wiring Waters' Empower software into BD's flow cytometry and PCR systems — is the acknowledged execution hurdle, and roughly 39% of shares now sit with former BD holders who may not be long-term believers at this price.

For a portfolio, this is a growth-and-momentum sleeve position, not a value or income holding — the aggressive end of a barbell, correctly paired with dividend names rather than mistaken for one. The factor stack says the story is real and improving, but the market is already pricing a lot of the transformation. The judgment is not that Waters is cheap; it is that Waters is no longer the same company the scoreboard says it was, and the investor who uses the adjusted numbers rather than the 240x mirage is the one with a defensible hold.

The rally is real. So is the price that now embeds much of the good news — which is precisely when a process, not hope, decides whether paying up is justified.